[Exudative age-related macular degeneration: efficacy and limits of the different treatments].
Ocular neovascularizations are responsible for irreversible loss of vision in various diseases, including age-related macular degeneration. Treatments have changed greatly, and photodynamic therapy with verteporfin has come into common use. However, the visual prognosis remains poor. The recent approval of new antiangiogenic molecules such as ranibizumab and pegaptanib should allow for new therapeutical possibilities. The unapproved ophthalmological use of bevacizumab requires further studies. This paper updates what is known about old and new neovascularization treatments: their mechanism of action, their efficacy, and their toxicity. It reviews the principal clinical studies, and concludes with the recognized recommendations. For the first time, ophthalmologists can hope not only to stabilize loss of vision, but also to improve visual acuity. Complementary treatments can now be tested in associations, concomitantly or not, with the hope of improving visual results.
Polak
M Berdugo
MB
Centre de Recherche des Cordeliers, Université Pierre et Marie Curie, Paris 6, UMRS 872, Paris, France. marianne.berdugo@gmail.com
Behar-Cohen
F
F
D000368:Aged; D000375:Aging / Q000502:physiology*; D003229:Conjunctival Diseases / Q000209:etiology*; D005260:Female; D006801:Humans; D008268:Macular Degeneration / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D010778:Photochemotherapy / Q000379:methods*; D011166:Porphyrins / Q000627:therapeutic use*; D000077362:Verteporfin; D014792:Visual Acuity
D011166:Porphyrins; D000077362:Verteporfin